<?xml version='1.0' encoding='utf-8'?>
<document id="21223639"><sentence text="Application of validated RP-HPLC method for simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles."><entity charOffset="74-83" id="DDI-PubMed.21223639.s1.e0" text="docetaxel" /><entity charOffset="88-100" id="DDI-PubMed.21223639.s1.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.21223639.s1.e0" e2="DDI-PubMed.21223639.s1.e0" /><pair ddi="false" e1="DDI-PubMed.21223639.s1.e0" e2="DDI-PubMed.21223639.s1.e1" /></sentence><sentence text="Docetaxel has significant single agent activity in prostate cancer and ketoconazole also has activity as a second line hormonal agent"><entity charOffset="0-9" id="DDI-PubMed.21223639.s2.e0" text="Docetaxel" /><entity charOffset="71-83" id="DDI-PubMed.21223639.s2.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.21223639.s2.e0" e2="DDI-PubMed.21223639.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21223639.s2.e0" e2="DDI-PubMed.21223639.s2.e1" /></sentence><sentence text=" In vitro, ketoconazole is synergistic with some chemotherapy agents by enhancing the intracellular retention of the cytotoxic agent"><entity charOffset="11-23" id="DDI-PubMed.21223639.s3.e0" text="ketoconazole" /></sentence><sentence text=" A potential drug-drug interaction exists though between docetaxel and ketoconazole because both agents are metabolized hepatically by the cytochrome P-450 system"><entity charOffset="57-66" id="DDI-PubMed.21223639.s4.e0" text="docetaxel" /><entity charOffset="71-83" id="DDI-PubMed.21223639.s4.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.21223639.s4.e0" e2="DDI-PubMed.21223639.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21223639.s4.e0" e2="DDI-PubMed.21223639.s4.e1" /></sentence><sentence text=" Hence, a nanoparticulate system was formulated by loading both drugs for tumor targeting" /><sentence text=" Assay and in vitro release of the formulation were conducted by developing simple, precise, accurate, and validated analytical method for simultaneous determination docetaxel and ketoconazole using reversed-phase high-performance liquid chromatography (RP-HPLC)"><entity charOffset="166-175" id="DDI-PubMed.21223639.s6.e0" text="docetaxel" /><entity charOffset="180-192" id="DDI-PubMed.21223639.s6.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.21223639.s6.e0" e2="DDI-PubMed.21223639.s6.e0" /><pair ddi="false" e1="DDI-PubMed.21223639.s6.e0" e2="DDI-PubMed.21223639.s6.e1" /></sentence><sentence text=" The RP-HPLC method was developed using Waters Symmetry C(18) column (25 cm × 4" /><sentence text="5 mm, 5 μm) with a mobile phase consisting of acetonitrile and 0"><entity charOffset="46-58" id="DDI-PubMed.21223639.s8.e0" text="acetonitrile" /></sentence><sentence text="2% triethylamine pH adjusted to 6"><entity charOffset="3-16" id="DDI-PubMed.21223639.s9.e0" text="triethylamine" /></sentence><sentence text="4 (48:52, v/v) at flow rate of 1 mL/min" /><sentence text=" Intra-day and inter-day variations were less than 2% over the linearity range, 0" /><sentence text="5-20 μg/mL" /><sentence text=" The proposed two methods were successfully applied for the determination of docetaxel and ketoconazole in solid lipid nanoparticles"><entity charOffset="77-86" id="DDI-PubMed.21223639.s13.e0" text="docetaxel" /><entity charOffset="91-103" id="DDI-PubMed.21223639.s13.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.21223639.s13.e0" e2="DDI-PubMed.21223639.s13.e0" /><pair ddi="false" e1="DDI-PubMed.21223639.s13.e0" e2="DDI-PubMed.21223639.s13.e1" /></sentence><sentence text="" /></document>